TY - JOUR
T1 - Validation of the MCL35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network
AU - Rauert-Wunderlich, Hilka
AU - Mottok, Anja
AU - Scott, David W.
AU - Rimsza, Lisa M.
AU - Ott, German
AU - Klapper, Wolfram
AU - Unterhalt, Michael
AU - Kluin-Nelemans, Hanneke C.
AU - Hermine, Olivier
AU - Hartmann, Sylvia
AU - Thorns, Christoph
AU - Rymkiewicz, Grzegorz
AU - Holte, Harald
AU - Dreyling, Martin
AU - Hoster, Eva
AU - Rosenwald, Andreas
N1 - Publisher Copyright:
© 2018 British Society for Haematology and John Wiley & Sons Ltd
PY - 2019/2
Y1 - 2019/2
N2 - Mantle cell lymphoma (MCL) is still considered incurable and the course of the disease is highly variable. Established risk factors include the Mantle Cell Lymphoma International Prognostic Index (MIPI) and the quantification of the proliferation rate of the tumour cells, e.g. by Ki-67 immunohistochemistry. In this study, we aimed to validate the prognostic value of the gene expression-based MCL35 proliferation assay in patient cohorts from randomized trials of the European Mantle Cell Lymphoma Network. Using this assay, we analysed the gene expression proliferation signature in routine diagnostic lymph node specimens from MCL Younger and MCL Elderly trial patients, and the calculated MCL35 score was used to assign MCL patients to low (61%), standard (27%) or high (12%) risk groups with significantly different outcomes. We confirm here in our prospective clinical trial cohort of MCL patients, that the MCL35 assay is strongly prognostic, providing additional information to the Ki-67 index and the MIPI. Thus, this robust assay may assist in making treatment decisions or in devising risk-adapted prospective clinical trials in the future.
AB - Mantle cell lymphoma (MCL) is still considered incurable and the course of the disease is highly variable. Established risk factors include the Mantle Cell Lymphoma International Prognostic Index (MIPI) and the quantification of the proliferation rate of the tumour cells, e.g. by Ki-67 immunohistochemistry. In this study, we aimed to validate the prognostic value of the gene expression-based MCL35 proliferation assay in patient cohorts from randomized trials of the European Mantle Cell Lymphoma Network. Using this assay, we analysed the gene expression proliferation signature in routine diagnostic lymph node specimens from MCL Younger and MCL Elderly trial patients, and the calculated MCL35 score was used to assign MCL patients to low (61%), standard (27%) or high (12%) risk groups with significantly different outcomes. We confirm here in our prospective clinical trial cohort of MCL patients, that the MCL35 assay is strongly prognostic, providing additional information to the Ki-67 index and the MIPI. Thus, this robust assay may assist in making treatment decisions or in devising risk-adapted prospective clinical trials in the future.
KW - gene expression analysis
KW - mantle cell lymphoma
KW - prognostic biomarker
KW - proliferation signature
KW - risk group stratification
UR - http://www.scopus.com/inward/record.url?scp=85052431790&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85052431790&partnerID=8YFLogxK
U2 - 10.1111/bjh.15519
DO - 10.1111/bjh.15519
M3 - Article
C2 - 30095158
AN - SCOPUS:85052431790
SN - 0007-1048
VL - 184
SP - 616
EP - 624
JO - British Journal of Haematology
JF - British Journal of Haematology
IS - 4
ER -